Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10022399 | 0.85 | GRIN2D (0.49) | CYP1A2CYP3A4MAPTCYP2C19NPSR1 | |
| SCHEMBL6345832 | 0.81 | CYP1A2 (0.54) | CYP1A2CYP3A4GAAALDH1A1HPGD | |
| SCHEMBL7048770 | 0.79 | HSD17B1 (0.47) | CYP1A2CYP3A4MAPTCYP2C19NPSR1 | |
| SCHEMBL21119018 | 0.78 | GABRA1 (0.47) | CYP1A2CYP3A4MAPTCYP2C19NPSR1 | |
| SCHEMBL6400171 | 0.77 | GABRA1 (0.54) | CYP1A2CYP3A4MAPTCYP2C19NPSR1 | |
| SCHEMBL2971769 | 0.76 | POLB (0.47) | CYP1A2GAALMNAALDH1A1HPGD | |
| SCHEMBL8606466 | 0.76 | GABRA1 (0.50) | CYP1A2CYP3A4MAPTCYP2C19NPSR1 | |
| SCHEMBL19425721 | 0.75 | HSD17B1 (0.55) | CYP1A2ALDH1A1HPGDHSD17B10CYP2A6 | |
| SCHEMBL18081311 | 0.75 | CYP1A2 (0.41) | CYP1A2CYP3A4MAPTCYP2C19NPSR1 | |
| SCHEMBL8531852 | 0.74 | CYP1A2 (0.47) | CYP1A2ALDH1A1HPGDHSD17B10CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924565-B1 | DIAMINOPYRIMIDINES AS P2X3 AND P3X2/3 MODULATORS | HOFFMANN LA ROCHE (CH) | 2016-09-14 | — | — | EP | disclosed |
| US-7776872-B2 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776872-B2 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776872-B2 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1924565-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P3X2/3 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007025900-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P3X2/3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007025900-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P3X2/3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049610-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049610-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049610-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049610-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | P2RX3, P2RX6, P2RX2 | CYP1A2 2871/4885CYP3A4 3254/4885MAPT 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.